Moderna on Thursday asked U.S. regulators to authorize low doses of its COVID-19 vaccine for children younger than 6, a move toward potentially allowing shots for millions of youths by summer.
"Antibodies produced by vaccinated and boosted people may not stop omicron SARS-CoV-2 strain from entering cells as well as it stops original virus," say Johns Hopkins researchers.
The U.S. Food and Drug Administration (FDA) on Monday approved the use of the antiviral therapy, remdesivir, to treat COVID-19 in infants four weeks and older.
